Literature DB >> 17581419

CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors.

W Glenn McCluggage1, Michael McKenna, Hilary A McBride.   

Abstract

Ovarian sex cord-stromal tumors comprise a heterogeneous group of neoplasms with wide morphological diversity, and they can be mistaken for a variety of other tumors. Some types, including granulosa and Sertoli cell tumor, may be confused with a neuroendocrine neoplasm. CD56 is a widely used neuroendocrine marker with a high sensitivity for neuroendocrine tumors and is commonly used as part of a panel to distinguish between a neuroendocrine neoplasm and other tumors in the differential diagnosis. In this study, we investigate CD56 staining in ovarian sex cord-stromal tumors. CD56 staining has not previously been studied in this group of neoplasms. We stained a large series of ovarian sex cord-stromal neoplasms (n = 85) with CD56. Neoplasms studied were adult granulosa cell tumor (n = 40), juvenile granulosa cell tumor (n = 8), Sertoli cell tumor (n = 1), Sertoli-Leydig cell tumor (n = 14), Leydig cell tumor (n = 2), steroid cell tumor, not otherwise specified (n = 2), sclerosing stromal tumor (n = 1), sex cord tumor with annular tubules (n = 2), and fibroma (n = 15). Three uterine tumors resembling ovarian sex cord tumor were also studied. Nonneoplastic ovaries, including 3 cases of pregnancy-related granulosa or Sertoli cell proliferation, were also included. In nontumorous ovaries, granulosa cells of follicular and corpus luteum cysts were consistently negative. The normal ovarian stroma was diffusely positive, as were the 3 pregnancy-related proliferations. All sex cord-stromal tumors except one were positive with CD56; staining ranged from focal to diffuse but was usually diffuse involving more than 50% of tumor cells. Staining was usually membranous with weaker cytoplasmic positivity. CD56 immunoreactivity is almost universal in ovarian sex cord-stromal tumors of all the major morphological types and is of no value in distinguishing a sex cord-stromal and a neuroendocrine neoplasm. Since CD56 is an extremely sensitive marker of ovarian sex cord-stromal tumors, it may be useful in the diagnosis of this group of neoplasms, especially in cases which are alpha inhibin or calretinin negative, and in distinguishing these from mimics which are CD56 negative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581419     DOI: 10.1097/01.pgp.0000236947.59463.87

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  12 in total

1.  Signet-ring stromal tumor of the ovary: an immunohistochemical and ultrastructural study with a review of the literature.

Authors:  Manabu Matsumoto; Yoshihiro Hayashi; Yuji Ohtsuki; Nobuo Ikegami; Makoto Toi; Mitsuko Iguchi; Makoto Hiroi
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

2.  Clinicopathologic features of ovarian Sertoli-Leydig cell tumors.

Authors:  Hai-Yan Zhang; Jia-Er Zhu; Wen Huang; Jin Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers.

Authors:  D P Hurrell; W G McCluggage
Journal:  J Clin Pathol       Date:  2006-12-20       Impact factor: 3.411

4.  Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.

Authors:  Andrew C Wood; John M Maris; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Raushan T Kurmasheva; Kathleen Whiteman; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-06-24       Impact factor: 3.167

5.  Cytologic features of sex cord-stromal tumors in women.

Authors:  Liz N Edmund; Abeer M Salama; Rajmohan Murali
Journal:  Cancer Cytopathol       Date:  2021-08-19       Impact factor: 4.264

6.  Granulosa Cell Tumors: Novel Predictors of Recurrence in Early-stage Patients.

Authors:  Sharif Sakr; Eman Abdulfatah; Sumi Thomas; Zaid Al-Wahab; Rafic Beydoun; Robert Morris; Rouba Ali-Fehmi; Sudeshna Bandyopadhyay
Journal:  Int J Gynecol Pathol       Date:  2017-05       Impact factor: 2.762

7.  Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Authors:  Kathleen R Whiteman; Holly A Johnson; Michele F Mayo; Charlene A Audette; Christina N Carrigan; Alyssa LaBelle; Lawrence Zukerberg; John M Lambert; Robert J Lutz
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

8.  Ovarian steroid cell tumour: correlation of histopathology with clinicopathologic features.

Authors:  Ghazala Mehdi; Hena A Ansari; Rana K Sherwani; Khaliqur Rahman; Nishat Akhtar
Journal:  Patholog Res Int       Date:  2011-03-02

9.  Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.

Authors:  Han Li; Zhang Yan; Wang Ning; Guo Xiao-Juan; Zang Cai-Hong; Jiang Jin-Hua; Ma Fang; Wang Qing-Duan
Journal:  J Biomed Biotechnol       Date:  2011-06-30

10.  Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary.

Authors:  Hans-Ullrich Völker; Sabine Engert; Andreas Cramer; Melanie Schmidt; Ulrike Kämmerer; Hans-Konrad Müller-Hermelink; Stefan Gattenlöhner
Journal:  Diagn Pathol       Date:  2008-07-09       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.